SG11201805364TA - Ointment - Google Patents
OintmentInfo
- Publication number
- SG11201805364TA SG11201805364TA SG11201805364TA SG11201805364TA SG11201805364TA SG 11201805364T A SG11201805364T A SG 11201805364TA SG 11201805364T A SG11201805364T A SG 11201805364TA SG 11201805364T A SG11201805364T A SG 11201805364TA SG 11201805364T A SG11201805364T A SG 11201805364TA
- Authority
- SG
- Singapore
- Prior art keywords
- osaka
- chuo
- shi
- otedori
- international
- Prior art date
Links
- 239000002674 ointment Substances 0.000 title abstract 5
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 abstract 1
- 241001590997 Moolgarda engeli Species 0.000 abstract 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- -1 oxazole compound Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015256784 | 2015-12-28 | ||
| PCT/JP2016/088843 WO2017115780A1 (en) | 2015-12-28 | 2016-12-27 | Ointment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805364TA true SG11201805364TA (en) | 2018-07-30 |
Family
ID=57851287
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805364TA SG11201805364TA (en) | 2015-12-28 | 2016-12-27 | Ointment |
| SG10201912634QA SG10201912634QA (en) | 2015-12-28 | 2016-12-27 | Ointment |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912634QA SG10201912634QA (en) | 2015-12-28 | 2016-12-27 | Ointment |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10588893B2 (da) |
| EP (1) | EP3397619B1 (da) |
| JP (3) | JP6873128B2 (da) |
| KR (2) | KR102643824B1 (da) |
| CN (1) | CN108473448A (da) |
| AU (1) | AU2016382036B2 (da) |
| CA (1) | CA3009734A1 (da) |
| DK (1) | DK3397619T3 (da) |
| ES (1) | ES2811849T3 (da) |
| HK (1) | HK1255187A1 (da) |
| MY (1) | MY197975A (da) |
| PH (1) | PH12018501346B1 (da) |
| SA (1) | SA518391908B1 (da) |
| SG (2) | SG11201805364TA (da) |
| TW (1) | TWI726027B (da) |
| WO (1) | WO2017115780A1 (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3095866A1 (en) | 2018-04-04 | 2019-10-10 | Otsuka Pharmaceutical Co., Ltd. | Oxazole compound crystal |
| JP7051968B2 (ja) * | 2019-10-09 | 2022-04-11 | 大塚製薬株式会社 | オキサゾール化合物結晶 |
| JP2024123673A (ja) * | 2023-03-01 | 2024-09-12 | ダイキン工業株式会社 | フッ素原子含有化合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6419963B1 (en) * | 2001-04-22 | 2002-07-16 | Sarfaraz K Niazi | Composition and method for the treatment of diaper rash using natural products |
| US7655717B2 (en) * | 2002-07-17 | 2010-02-02 | Mary J. Goulbourne | Ointment composition for treating decubitus ulcers and methods for its making and its use |
| TW200418516A (en) * | 2003-02-21 | 2004-10-01 | Shionogi & Co | Droplet dispersed ointment |
| JP5305914B2 (ja) * | 2005-11-15 | 2013-10-02 | 大塚製薬株式会社 | オキサゾール化合物及び医薬組成物 |
| CN102176913B (zh) * | 2008-10-08 | 2014-08-13 | 高田制药株式会社 | 外用的他克莫司制剂 |
| GB0907413D0 (en) * | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| JP5965187B2 (ja) * | 2012-03-30 | 2016-08-03 | 小林製薬株式会社 | 油性軟膏剤 |
| RU2015111236A (ru) | 2012-08-30 | 2016-10-20 | Оцука Фармасьютикал Ко., Лтд. | Способ получения производного оксазола |
-
2016
- 2016-12-26 TW TW105143190A patent/TWI726027B/zh active
- 2016-12-27 WO PCT/JP2016/088843 patent/WO2017115780A1/en active Application Filing
- 2016-12-27 US US16/064,618 patent/US10588893B2/en active Active
- 2016-12-27 KR KR1020187020807A patent/KR102643824B1/ko active IP Right Grant
- 2016-12-27 EP EP16828990.8A patent/EP3397619B1/en active Active
- 2016-12-27 JP JP2018525638A patent/JP6873128B2/ja active Active
- 2016-12-27 SG SG11201805364TA patent/SG11201805364TA/en unknown
- 2016-12-27 CA CA3009734A patent/CA3009734A1/en active Pending
- 2016-12-27 DK DK16828990.8T patent/DK3397619T3/da active
- 2016-12-27 ES ES16828990T patent/ES2811849T3/es active Active
- 2016-12-27 AU AU2016382036A patent/AU2016382036B2/en active Active
- 2016-12-27 MY MYPI2018001102A patent/MY197975A/en unknown
- 2016-12-27 SG SG10201912634QA patent/SG10201912634QA/en unknown
- 2016-12-27 CN CN201680076557.0A patent/CN108473448A/zh active Pending
- 2016-12-27 KR KR1020247006977A patent/KR20240034867A/ko not_active Application Discontinuation
-
2018
- 2018-06-22 PH PH12018501346A patent/PH12018501346B1/en unknown
- 2018-06-27 SA SA518391908A patent/SA518391908B1/ar unknown
- 2018-11-08 HK HK18114305.1A patent/HK1255187A1/zh unknown
-
2020
- 2020-02-05 US US16/782,259 patent/US20200171006A1/en not_active Abandoned
-
2021
- 2021-04-19 JP JP2021070099A patent/JP2021107437A/ja active Pending
-
2022
- 2022-01-03 US US17/567,582 patent/US20220117944A1/en not_active Abandoned
-
2023
- 2023-02-07 JP JP2023016555A patent/JP2023058571A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017115780A1 (en) | 2017-07-06 |
| EP3397619A1 (en) | 2018-11-07 |
| CA3009734A1 (en) | 2017-07-06 |
| PH12018501346A1 (en) | 2019-02-18 |
| US20200171006A1 (en) | 2020-06-04 |
| JP2023058571A (ja) | 2023-04-25 |
| AU2016382036A1 (en) | 2018-07-12 |
| ES2811849T3 (es) | 2021-03-15 |
| SG10201912634QA (en) | 2020-02-27 |
| KR20240034867A (ko) | 2024-03-14 |
| JP2019503989A (ja) | 2019-02-14 |
| KR20180097672A (ko) | 2018-08-31 |
| JP2021107437A (ja) | 2021-07-29 |
| AU2016382036B2 (en) | 2021-02-04 |
| US10588893B2 (en) | 2020-03-17 |
| TW201729806A (zh) | 2017-09-01 |
| PH12018501346B1 (en) | 2019-02-18 |
| KR102643824B1 (ko) | 2024-03-07 |
| CN108473448A (zh) | 2018-08-31 |
| EP3397619B1 (en) | 2020-07-29 |
| JP6873128B2 (ja) | 2021-05-19 |
| US20220117944A1 (en) | 2022-04-21 |
| US20190000810A1 (en) | 2019-01-03 |
| DK3397619T3 (da) | 2020-08-24 |
| HK1255187A1 (zh) | 2019-08-09 |
| MY197975A (en) | 2023-07-25 |
| SA518391908B1 (ar) | 2022-06-05 |
| NZ743851A (en) | 2021-09-24 |
| TWI726027B (zh) | 2021-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201806429PA (en) | Substituted piperidine compound and use thereof | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201903155XA (en) | Pharmaceutical compounds | |
| SG11201807426WA (en) | Immunomodulators | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201907435PA (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201806750WA (en) | Substituted 1,2,3-triazoles as nr2b-selective nmda modulators | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201407368VA (en) | Drug for preventing and/or treating polycystic kidney disease | |
| SG11201406973PA (en) | Complement pathway modulators and uses thereof | |
| SG11201906222WA (en) | Jak1 selective inhibitors | |
| SG11201804123VA (en) | Modulators of kv3 channels to treat pain | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201907774VA (en) | Sulfoximine glycosidase inhibitors | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch |